Effects of acute doses of oxiracetam in the scopolamine model of human amnesia
Abstract The scopolamine model of amnesia has been used to test the pharmacodynamic efficacy of oxiracetam in 12 healthy volunteers. The subjects were divided into four experimental groups, according to a double-blind cross over incomplete randomized block design. After a baseline neuropsychological...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1993 |
|---|
| Umfang: |
6 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Psychopharmacology - 1959, 110(1993) vom: Apr., Seite 421-426 |
| Übergeordnetes Werk: |
volume:110 ; year:1993 ; month:04 ; pages:421-426 ; extent:6 |
| Links: |
|---|
| Katalog-ID: |
NLEJ200714333 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ200714333 | ||
| 003 | DE-627 | ||
| 005 | 20230506092727.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070527s1993 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ200714333 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Effects of acute doses of oxiracetam in the scopolamine model of human amnesia |
| 264 | 1 | |c 1993 | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Abstract The scopolamine model of amnesia has been used to test the pharmacodynamic efficacy of oxiracetam in 12 healthy volunteers. The subjects were divided into four experimental groups, according to a double-blind cross over incomplete randomized block design. After a baseline neuropsychological examination, each subject received in two separate sessions one of the following treatments, as acute oral doses: oxiracetam 800, 1600, 2400 mg or placebo. One hour after treatment scopolamine hydrobromide (0.5 mg) was given subcutaneously. The cognitive performance was tested before and 1, 2, 3 and 25 h after scopolamine administration. Scopolamine caused a deterioration of performance of verbal episodic memory, semantic memory and attention tests. In comparison to placebo, oxiracetam improved the overall test performance, with a statistically significant difference at the dose of 1600 mg on delayed recall of word lists, and showed dose-related antagonism of scopolamine-induced effects also on semantic memory and attention. The efficacy of an acute dose of oxiracetam in reducing scopolamine-induced cognitive impairment supports the potential usefulness of this pharmacological model of amnesia for studying the effects of cognition enhancers in humans. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Preda, Laura |4 oth | |
| 700 | 1 | |a Alberoni, Margherita |4 oth | |
| 700 | 1 | |a Bressi, Sergio |4 oth | |
| 700 | 1 | |a Cattaneo, Carlo |4 oth | |
| 700 | 1 | |a Parini, Jacopo |4 oth | |
| 700 | 1 | |a Canal, Nicola |4 oth | |
| 700 | 1 | |a Franceschi, Massimo |4 oth | |
| 773 | 0 | 8 | |i in |t Psychopharmacology |d 1959 |g 110(1993) vom: Apr., Seite 421-426 |w (DE-627)NLEJ188990615 |w (DE-600)2066933-1 |x 1432-2072 |7 nnns |
| 773 | 1 | 8 | |g volume:110 |g year:1993 |g month:04 |g pages:421-426 |g extent:6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF02244648 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 110 |j 1993 |c 4 |h 421-426 |g 6 | ||
| matchkey_str |
article:14322072:1993----::fetoaueoeooiaeaitecplmnm |
|---|---|
| hierarchy_sort_str |
1993 |
| publishDate |
1993 |
| allfields |
(DE-627)NLEJ200714333 DE-627 ger DE-627 rakwb eng Effects of acute doses of oxiracetam in the scopolamine model of human amnesia 1993 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract The scopolamine model of amnesia has been used to test the pharmacodynamic efficacy of oxiracetam in 12 healthy volunteers. The subjects were divided into four experimental groups, according to a double-blind cross over incomplete randomized block design. After a baseline neuropsychological examination, each subject received in two separate sessions one of the following treatments, as acute oral doses: oxiracetam 800, 1600, 2400 mg or placebo. One hour after treatment scopolamine hydrobromide (0.5 mg) was given subcutaneously. The cognitive performance was tested before and 1, 2, 3 and 25 h after scopolamine administration. Scopolamine caused a deterioration of performance of verbal episodic memory, semantic memory and attention tests. In comparison to placebo, oxiracetam improved the overall test performance, with a statistically significant difference at the dose of 1600 mg on delayed recall of word lists, and showed dose-related antagonism of scopolamine-induced effects also on semantic memory and attention. The efficacy of an acute dose of oxiracetam in reducing scopolamine-induced cognitive impairment supports the potential usefulness of this pharmacological model of amnesia for studying the effects of cognition enhancers in humans. Springer Online Journal Archives 1860-2002 Preda, Laura oth Alberoni, Margherita oth Bressi, Sergio oth Cattaneo, Carlo oth Parini, Jacopo oth Canal, Nicola oth Franceschi, Massimo oth in Psychopharmacology 1959 110(1993) vom: Apr., Seite 421-426 (DE-627)NLEJ188990615 (DE-600)2066933-1 1432-2072 nnns volume:110 year:1993 month:04 pages:421-426 extent:6 http://dx.doi.org/10.1007/BF02244648 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 110 1993 4 421-426 6 |
| spelling |
(DE-627)NLEJ200714333 DE-627 ger DE-627 rakwb eng Effects of acute doses of oxiracetam in the scopolamine model of human amnesia 1993 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract The scopolamine model of amnesia has been used to test the pharmacodynamic efficacy of oxiracetam in 12 healthy volunteers. The subjects were divided into four experimental groups, according to a double-blind cross over incomplete randomized block design. After a baseline neuropsychological examination, each subject received in two separate sessions one of the following treatments, as acute oral doses: oxiracetam 800, 1600, 2400 mg or placebo. One hour after treatment scopolamine hydrobromide (0.5 mg) was given subcutaneously. The cognitive performance was tested before and 1, 2, 3 and 25 h after scopolamine administration. Scopolamine caused a deterioration of performance of verbal episodic memory, semantic memory and attention tests. In comparison to placebo, oxiracetam improved the overall test performance, with a statistically significant difference at the dose of 1600 mg on delayed recall of word lists, and showed dose-related antagonism of scopolamine-induced effects also on semantic memory and attention. The efficacy of an acute dose of oxiracetam in reducing scopolamine-induced cognitive impairment supports the potential usefulness of this pharmacological model of amnesia for studying the effects of cognition enhancers in humans. Springer Online Journal Archives 1860-2002 Preda, Laura oth Alberoni, Margherita oth Bressi, Sergio oth Cattaneo, Carlo oth Parini, Jacopo oth Canal, Nicola oth Franceschi, Massimo oth in Psychopharmacology 1959 110(1993) vom: Apr., Seite 421-426 (DE-627)NLEJ188990615 (DE-600)2066933-1 1432-2072 nnns volume:110 year:1993 month:04 pages:421-426 extent:6 http://dx.doi.org/10.1007/BF02244648 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 110 1993 4 421-426 6 |
| allfields_unstemmed |
(DE-627)NLEJ200714333 DE-627 ger DE-627 rakwb eng Effects of acute doses of oxiracetam in the scopolamine model of human amnesia 1993 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract The scopolamine model of amnesia has been used to test the pharmacodynamic efficacy of oxiracetam in 12 healthy volunteers. The subjects were divided into four experimental groups, according to a double-blind cross over incomplete randomized block design. After a baseline neuropsychological examination, each subject received in two separate sessions one of the following treatments, as acute oral doses: oxiracetam 800, 1600, 2400 mg or placebo. One hour after treatment scopolamine hydrobromide (0.5 mg) was given subcutaneously. The cognitive performance was tested before and 1, 2, 3 and 25 h after scopolamine administration. Scopolamine caused a deterioration of performance of verbal episodic memory, semantic memory and attention tests. In comparison to placebo, oxiracetam improved the overall test performance, with a statistically significant difference at the dose of 1600 mg on delayed recall of word lists, and showed dose-related antagonism of scopolamine-induced effects also on semantic memory and attention. The efficacy of an acute dose of oxiracetam in reducing scopolamine-induced cognitive impairment supports the potential usefulness of this pharmacological model of amnesia for studying the effects of cognition enhancers in humans. Springer Online Journal Archives 1860-2002 Preda, Laura oth Alberoni, Margherita oth Bressi, Sergio oth Cattaneo, Carlo oth Parini, Jacopo oth Canal, Nicola oth Franceschi, Massimo oth in Psychopharmacology 1959 110(1993) vom: Apr., Seite 421-426 (DE-627)NLEJ188990615 (DE-600)2066933-1 1432-2072 nnns volume:110 year:1993 month:04 pages:421-426 extent:6 http://dx.doi.org/10.1007/BF02244648 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 110 1993 4 421-426 6 |
| allfieldsGer |
(DE-627)NLEJ200714333 DE-627 ger DE-627 rakwb eng Effects of acute doses of oxiracetam in the scopolamine model of human amnesia 1993 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract The scopolamine model of amnesia has been used to test the pharmacodynamic efficacy of oxiracetam in 12 healthy volunteers. The subjects were divided into four experimental groups, according to a double-blind cross over incomplete randomized block design. After a baseline neuropsychological examination, each subject received in two separate sessions one of the following treatments, as acute oral doses: oxiracetam 800, 1600, 2400 mg or placebo. One hour after treatment scopolamine hydrobromide (0.5 mg) was given subcutaneously. The cognitive performance was tested before and 1, 2, 3 and 25 h after scopolamine administration. Scopolamine caused a deterioration of performance of verbal episodic memory, semantic memory and attention tests. In comparison to placebo, oxiracetam improved the overall test performance, with a statistically significant difference at the dose of 1600 mg on delayed recall of word lists, and showed dose-related antagonism of scopolamine-induced effects also on semantic memory and attention. The efficacy of an acute dose of oxiracetam in reducing scopolamine-induced cognitive impairment supports the potential usefulness of this pharmacological model of amnesia for studying the effects of cognition enhancers in humans. Springer Online Journal Archives 1860-2002 Preda, Laura oth Alberoni, Margherita oth Bressi, Sergio oth Cattaneo, Carlo oth Parini, Jacopo oth Canal, Nicola oth Franceschi, Massimo oth in Psychopharmacology 1959 110(1993) vom: Apr., Seite 421-426 (DE-627)NLEJ188990615 (DE-600)2066933-1 1432-2072 nnns volume:110 year:1993 month:04 pages:421-426 extent:6 http://dx.doi.org/10.1007/BF02244648 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 110 1993 4 421-426 6 |
| allfieldsSound |
(DE-627)NLEJ200714333 DE-627 ger DE-627 rakwb eng Effects of acute doses of oxiracetam in the scopolamine model of human amnesia 1993 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Abstract The scopolamine model of amnesia has been used to test the pharmacodynamic efficacy of oxiracetam in 12 healthy volunteers. The subjects were divided into four experimental groups, according to a double-blind cross over incomplete randomized block design. After a baseline neuropsychological examination, each subject received in two separate sessions one of the following treatments, as acute oral doses: oxiracetam 800, 1600, 2400 mg or placebo. One hour after treatment scopolamine hydrobromide (0.5 mg) was given subcutaneously. The cognitive performance was tested before and 1, 2, 3 and 25 h after scopolamine administration. Scopolamine caused a deterioration of performance of verbal episodic memory, semantic memory and attention tests. In comparison to placebo, oxiracetam improved the overall test performance, with a statistically significant difference at the dose of 1600 mg on delayed recall of word lists, and showed dose-related antagonism of scopolamine-induced effects also on semantic memory and attention. The efficacy of an acute dose of oxiracetam in reducing scopolamine-induced cognitive impairment supports the potential usefulness of this pharmacological model of amnesia for studying the effects of cognition enhancers in humans. Springer Online Journal Archives 1860-2002 Preda, Laura oth Alberoni, Margherita oth Bressi, Sergio oth Cattaneo, Carlo oth Parini, Jacopo oth Canal, Nicola oth Franceschi, Massimo oth in Psychopharmacology 1959 110(1993) vom: Apr., Seite 421-426 (DE-627)NLEJ188990615 (DE-600)2066933-1 1432-2072 nnns volume:110 year:1993 month:04 pages:421-426 extent:6 http://dx.doi.org/10.1007/BF02244648 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 110 1993 4 421-426 6 |
| language |
English |
| source |
in Psychopharmacology 110(1993) vom: Apr., Seite 421-426 volume:110 year:1993 month:04 pages:421-426 extent:6 |
| sourceStr |
in Psychopharmacology 110(1993) vom: Apr., Seite 421-426 volume:110 year:1993 month:04 pages:421-426 extent:6 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Psychopharmacology |
| authorswithroles_txt_mv |
Preda, Laura @@oth@@ Alberoni, Margherita @@oth@@ Bressi, Sergio @@oth@@ Cattaneo, Carlo @@oth@@ Parini, Jacopo @@oth@@ Canal, Nicola @@oth@@ Franceschi, Massimo @@oth@@ |
| publishDateDaySort_date |
1993-04-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188990615 |
| id |
NLEJ200714333 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ200714333</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506092727.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070527s1993 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ200714333</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effects of acute doses of oxiracetam in the scopolamine model of human amnesia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The scopolamine model of amnesia has been used to test the pharmacodynamic efficacy of oxiracetam in 12 healthy volunteers. The subjects were divided into four experimental groups, according to a double-blind cross over incomplete randomized block design. After a baseline neuropsychological examination, each subject received in two separate sessions one of the following treatments, as acute oral doses: oxiracetam 800, 1600, 2400 mg or placebo. One hour after treatment scopolamine hydrobromide (0.5 mg) was given subcutaneously. The cognitive performance was tested before and 1, 2, 3 and 25 h after scopolamine administration. Scopolamine caused a deterioration of performance of verbal episodic memory, semantic memory and attention tests. In comparison to placebo, oxiracetam improved the overall test performance, with a statistically significant difference at the dose of 1600 mg on delayed recall of word lists, and showed dose-related antagonism of scopolamine-induced effects also on semantic memory and attention. The efficacy of an acute dose of oxiracetam in reducing scopolamine-induced cognitive impairment supports the potential usefulness of this pharmacological model of amnesia for studying the effects of cognition enhancers in humans.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Preda, Laura</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alberoni, Margherita</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bressi, Sergio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cattaneo, Carlo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parini, Jacopo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Canal, Nicola</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Franceschi, Massimo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Psychopharmacology</subfield><subfield code="d">1959</subfield><subfield code="g">110(1993) vom: Apr., Seite 421-426</subfield><subfield code="w">(DE-627)NLEJ188990615</subfield><subfield code="w">(DE-600)2066933-1</subfield><subfield code="x">1432-2072</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:110</subfield><subfield code="g">year:1993</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:421-426</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF02244648</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">110</subfield><subfield code="j">1993</subfield><subfield code="c">4</subfield><subfield code="h">421-426</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188990615 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1432-2072 |
| topic_title |
Effects of acute doses of oxiracetam in the scopolamine model of human amnesia |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
l p lp m a ma s b sb c c cc j p jp n c nc m f mf |
| hierarchy_parent_title |
Psychopharmacology |
| hierarchy_parent_id |
NLEJ188990615 |
| hierarchy_top_title |
Psychopharmacology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188990615 (DE-600)2066933-1 |
| title |
Effects of acute doses of oxiracetam in the scopolamine model of human amnesia |
| spellingShingle |
Effects of acute doses of oxiracetam in the scopolamine model of human amnesia |
| ctrlnum |
(DE-627)NLEJ200714333 |
| title_full |
Effects of acute doses of oxiracetam in the scopolamine model of human amnesia |
| journal |
Psychopharmacology |
| journalStr |
Psychopharmacology |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1993 |
| contenttype_str_mv |
zzz |
| container_start_page |
421 |
| container_volume |
110 |
| physical |
6 |
| format_se |
Elektronische Aufsätze |
| title_sort |
effects of acute doses of oxiracetam in the scopolamine model of human amnesia |
| title_auth |
Effects of acute doses of oxiracetam in the scopolamine model of human amnesia |
| abstract |
Abstract The scopolamine model of amnesia has been used to test the pharmacodynamic efficacy of oxiracetam in 12 healthy volunteers. The subjects were divided into four experimental groups, according to a double-blind cross over incomplete randomized block design. After a baseline neuropsychological examination, each subject received in two separate sessions one of the following treatments, as acute oral doses: oxiracetam 800, 1600, 2400 mg or placebo. One hour after treatment scopolamine hydrobromide (0.5 mg) was given subcutaneously. The cognitive performance was tested before and 1, 2, 3 and 25 h after scopolamine administration. Scopolamine caused a deterioration of performance of verbal episodic memory, semantic memory and attention tests. In comparison to placebo, oxiracetam improved the overall test performance, with a statistically significant difference at the dose of 1600 mg on delayed recall of word lists, and showed dose-related antagonism of scopolamine-induced effects also on semantic memory and attention. The efficacy of an acute dose of oxiracetam in reducing scopolamine-induced cognitive impairment supports the potential usefulness of this pharmacological model of amnesia for studying the effects of cognition enhancers in humans. |
| abstractGer |
Abstract The scopolamine model of amnesia has been used to test the pharmacodynamic efficacy of oxiracetam in 12 healthy volunteers. The subjects were divided into four experimental groups, according to a double-blind cross over incomplete randomized block design. After a baseline neuropsychological examination, each subject received in two separate sessions one of the following treatments, as acute oral doses: oxiracetam 800, 1600, 2400 mg or placebo. One hour after treatment scopolamine hydrobromide (0.5 mg) was given subcutaneously. The cognitive performance was tested before and 1, 2, 3 and 25 h after scopolamine administration. Scopolamine caused a deterioration of performance of verbal episodic memory, semantic memory and attention tests. In comparison to placebo, oxiracetam improved the overall test performance, with a statistically significant difference at the dose of 1600 mg on delayed recall of word lists, and showed dose-related antagonism of scopolamine-induced effects also on semantic memory and attention. The efficacy of an acute dose of oxiracetam in reducing scopolamine-induced cognitive impairment supports the potential usefulness of this pharmacological model of amnesia for studying the effects of cognition enhancers in humans. |
| abstract_unstemmed |
Abstract The scopolamine model of amnesia has been used to test the pharmacodynamic efficacy of oxiracetam in 12 healthy volunteers. The subjects were divided into four experimental groups, according to a double-blind cross over incomplete randomized block design. After a baseline neuropsychological examination, each subject received in two separate sessions one of the following treatments, as acute oral doses: oxiracetam 800, 1600, 2400 mg or placebo. One hour after treatment scopolamine hydrobromide (0.5 mg) was given subcutaneously. The cognitive performance was tested before and 1, 2, 3 and 25 h after scopolamine administration. Scopolamine caused a deterioration of performance of verbal episodic memory, semantic memory and attention tests. In comparison to placebo, oxiracetam improved the overall test performance, with a statistically significant difference at the dose of 1600 mg on delayed recall of word lists, and showed dose-related antagonism of scopolamine-induced effects also on semantic memory and attention. The efficacy of an acute dose of oxiracetam in reducing scopolamine-induced cognitive impairment supports the potential usefulness of this pharmacological model of amnesia for studying the effects of cognition enhancers in humans. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Effects of acute doses of oxiracetam in the scopolamine model of human amnesia |
| url |
http://dx.doi.org/10.1007/BF02244648 |
| remote_bool |
true |
| author2 |
Preda, Laura Alberoni, Margherita Bressi, Sergio Cattaneo, Carlo Parini, Jacopo Canal, Nicola Franceschi, Massimo |
| author2Str |
Preda, Laura Alberoni, Margherita Bressi, Sergio Cattaneo, Carlo Parini, Jacopo Canal, Nicola Franceschi, Massimo |
| ppnlink |
NLEJ188990615 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth |
| up_date |
2024-07-06T03:37:28.911Z |
| _version_ |
1803799283796803584 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ200714333</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230506092727.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070527s1993 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ200714333</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Effects of acute doses of oxiracetam in the scopolamine model of human amnesia</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1993</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract The scopolamine model of amnesia has been used to test the pharmacodynamic efficacy of oxiracetam in 12 healthy volunteers. The subjects were divided into four experimental groups, according to a double-blind cross over incomplete randomized block design. After a baseline neuropsychological examination, each subject received in two separate sessions one of the following treatments, as acute oral doses: oxiracetam 800, 1600, 2400 mg or placebo. One hour after treatment scopolamine hydrobromide (0.5 mg) was given subcutaneously. The cognitive performance was tested before and 1, 2, 3 and 25 h after scopolamine administration. Scopolamine caused a deterioration of performance of verbal episodic memory, semantic memory and attention tests. In comparison to placebo, oxiracetam improved the overall test performance, with a statistically significant difference at the dose of 1600 mg on delayed recall of word lists, and showed dose-related antagonism of scopolamine-induced effects also on semantic memory and attention. The efficacy of an acute dose of oxiracetam in reducing scopolamine-induced cognitive impairment supports the potential usefulness of this pharmacological model of amnesia for studying the effects of cognition enhancers in humans.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Preda, Laura</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Alberoni, Margherita</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bressi, Sergio</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Cattaneo, Carlo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Parini, Jacopo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Canal, Nicola</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Franceschi, Massimo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Psychopharmacology</subfield><subfield code="d">1959</subfield><subfield code="g">110(1993) vom: Apr., Seite 421-426</subfield><subfield code="w">(DE-627)NLEJ188990615</subfield><subfield code="w">(DE-600)2066933-1</subfield><subfield code="x">1432-2072</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:110</subfield><subfield code="g">year:1993</subfield><subfield code="g">month:04</subfield><subfield code="g">pages:421-426</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF02244648</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">110</subfield><subfield code="j">1993</subfield><subfield code="c">4</subfield><subfield code="h">421-426</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| score |
7.4006987 |